XML 14 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Revenues:    
License and milestone fees $ 13,167 $ 933
Research and development support 1,990 1,377
Clinical materials revenue 8 1,781
Royalty revenue 2,053  
Total revenues 17,218 4,091
Operating Expenses:    
Research and development 22,029 23,700
General and administrative 6,526 5,639
Total operating expenses 28,555 29,339
Loss from operations (11,337) (25,248)
Other income, net 111 56
Net loss (11,226) (25,192)
Basic and diluted net loss per common share (in dollars per share) $ (0.13) $ (0.30)
Basic and diluted weighted average common shares outstanding (in shares) 85,010 83,350
Total comprehensive loss $ (11,226) $ (25,192)